孕激素主导卵巢刺激在赠卵中的应用:选择性生育力保存的模型?
回顾性队列研究分析2016至2018年间187个玻璃化赠卵受者周期,比较供者使用地索高诺孕酮行孕激素主导卵巢刺激(PPOS)与加尼瑞克GnRH拮抗剂对卵母细胞能力、胚胎发育及活产率的影响。结果显示两组在复苏存活率、受精率、胚胎发育及调整后活产率上均无显著差异。
要点
- 供者PPOS方案与GnRH拮抗剂方案相比,受者临床妊娠率和活产率无显著差异。
- 调整混杂因素后,PPOS组与拮抗剂组活产率仍无统计学差异(OR 0.74,95%CI 0.37-1.47)。
- PPOS适用于选择性生育力保存及全胚冷冻策略中的LH峰抑制。
核心结论
- 玻璃化赠卵受者的生殖结局不受供者PPOS治疗影响。
- PPOS适用于选择性生育力保存和全胚冷冻策略中的LH峰抑制。
研究设计与样本
- 回顾性队列研究,2016年至2018年间纳入187个玻璃化赠卵受者周期。
- 供者使用地索高诺孕酮行PPOS(DSG组)或加尼瑞克GnRH拮抗剂(ANT组)抑制LH峰。
- 受者年龄小于50岁,接受来自DSG捐赠周期(DSG-R)或ANT捐赠周期(ANT-R)的玻璃化卵母细胞。
主要发现
- 每受者平均复苏10.07±3.54枚卵母细胞,复苏率80.7%,平均受精5.90±2.89枚,受精率72.6%。
- 187名受者中168名完成胚胎移植,获得94例临床妊娠和81例活产。
- DSG-R组与ANT-R组相比,复苏存活率、受精率和胚胎发育均无显著差异。
- DSG-R组与ANT-R组每受者周期的临床妊娠率分别为47.7%与52.5%(P=0.513),活产率分别为39.5%与46.5%(P=0.336),均无统计学显著差异。
- 调整相关因素后,DSG来源与ANT来源玻璃化卵母细胞的活产率无统计学差异(OR 0.74,95%CI 0.37-1.47)。
临床怎么用
- 原文结论认为PPOS适用于选择性生育力保存和全胚冷冻策略中的LH峰抑制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does type of LH peak suppression (progesterone-primed ovarian stimulation [PPOS] versus gonadotrophin releasing hormone [GnRH] antagonist) affect oocyte competence, embryo development and live birth rates in recipients of vitrified donated oocytes? DESIGN: Retrospective cohort study conducted between 2016 and 2018, involving 187 recipient cycles of donated vitrified oocytes. Oocyte donors were stimulated under LH suppression with desogestrel for PPOS (DSG group) or ganirelix GnRH antagonist (ANT group). Recipients younger than 50 years received vitrified oocytes from DSG donation cycles (DSG-R) or ANT donation cycles (ANT-R). RESULTS: A mean of 10.07 ± 3.54 oocytes per recipient were warmed (survival rate of 80.7%), and 5.90 ± 2.89 were fertilized (fertilization rate 72.6%). Out of 187 recipients, 168 achieved embryo transfers. No significant differences were found in warming survival rates, fertilization rates and embryo development between DSG-R and ANT-R groups. Ninety-four clinical pregnancies and 81 live births were achieved. No statistically significant differences were found in clinical pregnancy rates (47.7% versus 52.5, P = 0.513) and live birth rates (39.5% versus 46.5%, P = 0.336) per recipient cycle between DSG-R and ANT-R, respectively. Multivariable logistic regression was applied to assess the effect of treating oocyte donors. Live birth rate adjusted for associated factors was not statistically different between vitrified oocytes from DSG or ANT (OR 0.74, 95% CI 0.37 to 1.47). CONCLUSION: Reproductive outcomes of recipients of vitrified oocytes are not affected by donor PPOS treatment. PPOS is suitable for suppressing LH peak in elective fertility preservation and in freeze-all strategies.
引用
- Devesa M, Racca A, Clúa E, et al. Progesterone-primed ovarian stimulation in oocyte donation: a model for elective fertility preservation? Reprod Biomed Online. 2022. PMID: 35339364. doi:10.1016/j.rbmo.2022.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。